Browse
Submit Data
Databases
API
Help

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A randomized, multicenter non-inferiority trial of 1-day versus 3-day dexamethasone in combination with palonosetron for prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

ABSTRACT: Interventions: dexamethasone day1-3 plus palonosetron dexamethasone day1 plus palonosetron Primary outcome(s): Percentage of patients with complete response (no vomiting and no rescue medication) during day1-5 after moderately emetogenic chemotherapy Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer, Lung Cancer, Breast Cancer

PROVIDER: 2624800 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

The efficacy of combination antiemetic therapy with Olanzapine, Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving Moderately Emetogenic Chemotherapy

Project description:Interventions: Palonosetron, dexamethasone, olanzapine Palonosetron, dexamethasone Primary outcome(s): Complete response rate for the overall phase(0-120 hours), defined as no emetic episodes and no use of rescue medication Study Design: Cross-over Randomized

| 2649465 | ecrin-mdr-crc

Randomized Phase II trial of Palonosetron/Dexamethasone concurrent therapy with prevention of CINV according to chemotherapy including Oxaliplatin or Irinotecan in patients with advanced colorectal cancer.

Project description:Interventions: Group A(Normal Group of Dexamethasone) Day1 Dexamethasone 9.9mg/body (i.v) Palonosetron 0.75mg/body Day2-3 Dexamethasone 8mg/body (p.o) This administration method repeated 4 courses. Group B(Loss Group of Dexamethasone) Day1 Dexamethasone 9.9mg/body (i.v) Palonosetron 0.75mg/body Day2-3 Dexamethasone 2mg/body (p.o) This administration method repeated 4 courses. Primary outcome(s): Delayed(24-120hr) complete response rate Study Design: Parallel Randomized

| 2620971 | ecrin-mdr-crc

A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)

Project description:Interventions: Palonosetron 0.75mg/body Dexamethasone 9.9mg/body Palonosetron 0.75mg/body Primary outcome(s): Complete response rate (overall period) Study Design: Parallel Randomized

| 2628600 | ecrin-mdr-crc

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Project description:RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.

| 2033103 | ecrin-mdr-crc

Efficacy of preventive treatment of nausea and vomiting induced by chemotherapy of Colorectal Cancer

Project description:Interventions: Palonosetron/Dexamethasone Palonosetron/Dexamethasone plus aprepitant Primary outcome(s): Complete Response Rate Study Design: Parallel Randomized

| 2621147 | ecrin-mdr-crc

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

Project description:Interventions: Group A: * 1st course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day. * 2nd course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 13.2mg i.v. on 3rd day. Group B: * 1st course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 13.2mg i.v. on 3rd day. * 2nd course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day. Primary outcome(s): * Blood concentration of dexamethasone Study Design: Cross-over Randomized

| 2629132 | ecrin-mdr-crc

Effects of dexamethasone on gene expression in rat pancreatic AR42J cell line

Project description:The rat pancreatic cell line AR42J is relatively undifferentiated under normal culture conditions. When the glucocorticoid dexamethasone is added to the medium the cells display a dramatic decrease in proliferative rate and are induced to a more exocrine phenotype that includes increased expression of exocrine pancreas products (digestive enzymes) and more developed regulated secretion. We used microarray to determine changes in gene expression comparing control (without dexamethasone) vs induced (plus dexamethasone).

2015-09-11 | GSE72907 | GEO

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.

Project description: Not available

| S-EPMC7747608 | biostudies-literature

Efficacy and safety of palonosetron and dexamethasone in patients who haven’t responded to conventional antiemetic agents; granisetron and dexamethasone

Project description:Interventions: Day 1 Palonosetoron 0.75mg/body and dexamethasone 12mg/body should be administered 30 minutes prior to chemotherapy Day 2-3 Dexamethasone 4mg/body should be administered orally. Primary outcome(s): Complete Response rate Study Design: Single arm Non-randomized

| 2624980 | ecrin-mdr-crc

A validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone. (AVOID)

Project description:Interventions: Dexamethasone 13.2mg/body i.v.(day1) Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Hypersensitivity reaction incidence Study Design: Single arm Non-randomized

| 2625136 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data